Wall Street Futures Steady as AI Rally Offsets Middle East Tensions 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
Lam Research Expands AI-Powered Semiconductor Tools and Arizona Operations 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
ASX Shares Plunge as Rising Tech Upgrade Costs Shake Investor Confidence 
Australia Inflation Cools in April as Fuel Prices Ease, But Core CPI Remains Sticky 
Nikkei Hits Record High as AI Chip Stocks Power Japan Market Rally 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Sri Lanka Central Bank Surprises Markets With 100 Basis Point Rate Hike Amid Inflation and Currency Pressure 
Puerto Rico Economic Development Chief Resigns Amid Government Shake-Up 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Dollar Slips as Iran Peace Hopes Ease Rate Hike Fears 
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market 
Texas Sues Meta Over WhatsApp Encryption Claims 
Australia Urged to Simplify Regulations to Revive IPO Market and Boost Innovation 
Lotte Biologics has completed the acquisition process to take over the manufacturing facility of Bristol Myers Squibb in Syracuse, New York, for $160 million. The drug manufacturing unit of the Lotte Group confirmed the deal on Tuesday, Jan. 3.
With the addition of Bristol Myers Squibb’s plant in Lotte Biologics’ property portfolio, the fifth-largest retail-chemical company in South Korea has officially jumped into the contract manufacturing business. This acquisition also comes after the Lotte Group launched Lotte Biologics, a biological CDMO (Contract Development Manufacturing Organization), in June 2022.
As per The Korea Herald, the company actually completed the takeover of the Bristol Myers Squibb facility on Dec. 31. All of its existing manufacturing contract agreements for drug production are also included in the acquisition. It was reported that these deals are worth $220 million and deliveries are to be carried out over the next three years.
The South Korean CDMO firm also revealed its plans to invest $70 million to upgrade the manufacturing facility in Syracuse. This investment will add manufacturing lines for drug substances, antibody-drug conjugates, and other drug products.
As Lotte Biologics buys Bristol Myers Squibb's manufacturing facility, it will also be creating around 70 jobs, and they will be assigned to various roles at the plant. This will be an addition to the existing BMS workforce, which is said to be 450 in number.
“Based on the successful acquisition of the Syracuse Plant, Lotte Biologics will emerge as a global CDMO that can achieve 1.5 trillion KRW in sales, a 30% operating margin, and a corporate value of 20 trillion KRW by 2030 by providing innovative medicines to patients,” Lotte Biologics’ chief executive officer, Richard Lee, said in a press release. “We will continue to grow at a rapid pace.”
The CEO further said that his goal is to successfully establish the company as a new growth engine for the Lotte Group. Lee will work on achieving this ambition by signing partnership deals with some global pharmaceutical companies and securing other bio ventures.
